Veradermics, Incorporated
MANE
$98.49
-$5.34-5.14%
NYSE
| 06/30/2026 | 03/31/2026 | 12/31/2025 | 06/30/2025 | ||
|---|---|---|---|---|---|
| Revenue | -- | -- | -- | -- | |
| Total Other Revenue | -- | -- | -- | -- | |
| Total Revenue | -- | -- | -- | -- | |
| Cost of Revenue | -- | -- | -- | -- | |
| Gross Profit | -- | -- | -- | -- | |
| SG&A Expenses | 10.95M | 8.94M | 4.82M | 1.74M | |
| Depreciation & Amortization | -- | -- | -- | -- | |
| Other Operating Expenses | -- | -- | -- | -- | |
| Total Operating Expenses | 29.55M | 29.86M | 23.01M | 16.07M | |
| Operating Income | -29.55M | -29.86M | -23.01M | -16.07M | |
| Income Before Tax | -23.50M | -27.23M | -21.85M | -15.65M | |
| Income Tax Expenses | -- | -- | -- | -- | |
| Earnings from Continuing Operations | -23.50M | -27.23M | -21.85M | -15.65M | |
| Earnings from Discontinued Operations | -- | -- | -- | -- | |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | |
| Minority Interest in Earnings | -- | -- | -- | -- | |
| Net Income | -23.50M | -27.23M | -21.85M | -15.65M | |
| EBIT | -29.55M | -29.86M | -23.01M | -16.07M | |
| EBITDA | -- | -- | -- | -- | |
| EPS Basic | -0.58 | -1.32 | -37.62 | -24.19 | |
| Normalized Basic EPS | -0.36 | -0.75 | -18.21 | -13.13 | |
| EPS Diluted | -0.58 | -1.32 | -37.62 | -24.19 | |
| Normalized Diluted EPS | -0.36 | -0.75 | -18.21 | -13.13 | |
| Average Basic Shares Outstanding | 40.44M | 22.70M | 749.80K | 744.60K | |
| Average Diluted Shares Outstanding | 40.44M | 22.70M | 749.80K | 744.60K | |
| Dividend Per Share | -- | -- | -- | -- | |
| Payout Ratio | -- | -- | -- | -- | |